VALANX Biotech and Fina Biosolutions Introduce ClickCRM for Rapid Conjugate Vaccine Development

VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug and diagnostics discovery, and Fina Biosolutions LLC (FinaBio), experts in conjugate vaccine development and conjugate chemistry, today announced the signing of a joint IP and licensing agreement.

CD70 CAR-T by UTC Therapeutics for Burkitt Lymphoma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

August 10, 2023

Exercise shapes our gut health, study finds

Accelerometer-based study reveals physical activity levels significantly influence gut microbiota composition, linking moderate and vigorous exercise to beneficial microbial diversity and function.

February 4, 2024

Opinion | ‘I Guess You Negotiate With a Mugger’: What We Heard This Week

“I guess you negotiate with a mugger when they show up. It’s your money or your life.” — Craig Garthwaite, PhD, an economist at Northwestern

December 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.